The medicine finest recognized for dramatic weight reduction are quietly turning into a flashpoint within the competitors for expertise, and employers who’ve been gradual to behave on protection could also be operating out of time.
In accordance with NFP’s (an Aon firm) 2026 U.S. Advantages Development Report, almost one-third of workers say they might swap employers to realize entry to GLP-1 protection, elevating these medicines from a line merchandise within the pharmacy price range to a workforce technique downside.
On the identical time, 51% of employers now cite GLP-1 diabetes and weight-loss medicines as the highest driver of prescription drug spend, surpassing oncology and autoimmune therapies.
The result’s a strategic bind. Employers can’t simply afford to cowl these medicine broadly, and so they more and more can’t afford to not.
Two tiers of GLP-1 protection
The NFP report describes a market that has successfully break up in two: GLP-1 protection for diabetes, the place medical justification is clearer, and protection for weight administration, the place employer selections differ dramatically and cost-benefit calculations stay unsettled.
Some employers have been reluctant to increase protection to the weight-loss indication. Protection for weight problems medicine, together with GLP‑1 medicines, rose to 44% of huge employers (500+ workers) in 2024, and 64% of the biggest employers (20,000+ workers) now supply this protection, based on information from Mercer.
Pharmacy profit managers make it comparatively straightforward to toggle that protection distinction on or off, and a great quantity have accomplished so. However worker expectations, formed by the cultural ubiquity of medication like Ozempic and Wegovy, haven’t adopted go well with.
Worker satisfaction with prescription cost-sharing displays the stress. The NFP report discovered satisfaction dropped from 73% to 66% yr over yr, and 47% of workers now use web sites or apps to seek out decrease drug costs. HR leaders can take this as a sign that out-of-pocket prices have gotten unattractive for a lot of staff.
Learn extra | Exploding GLP-1 prices: How employers are scrambling to handle
New GLP-1 fashions emerge, however tradeoffs stay
The market is starting to reply. CVS Caremark just lately introduced a collaboration with telehealth firm eMed that enables eligible workers to buy GLP-1s on-line with wraparound medical assist, together with weekly check-ins, facet impact administration and biannual blood testing. Employers can decide how a lot of the fee to subsidize, providing a center path between full formulary protection and nothing in any respect.
Aon, which piloted an identical eMed program for its personal workers, reported that contributors stayed on the remedy longer and noticed significant enhancements in weight and BMI. About 9% of eligible Aon workers enrolled, based on reporting in Axios.
Nonetheless, the economics are unresolved. Analysis from the Worker Profit Analysis Institute estimates that including GLP-1 protection for weight reduction might enhance employer medical health insurance premiums by between 5.3% and 13.8%, relying on eligibility standards and adherence patterns. Any downstream financial savings from improved well being outcomes, in the meantime, might take years to materialize.
Regardless of the prospect of ready for long-term, health-driven premium financial savings, the NFP information means that doing nothing carries its personal price. With almost a 3rd of workers keen to alter jobs over this profit, GLP-1 protection is not a medical resolution delegated to the advantages workforce. It’s a whole rewards resolution that belongs in conversations about expertise competitiveness.
Hybrid fashions just like the eMed partnership might supply employers a technique to act with out totally absorbing the fee, however the window for a measured response is narrowing as worker expectations proceed to rise.
